Gemeinsamer Bundesausschuss

Resolution

of the Federal Joint Committee on an Amendment of the Pharmaceuticals Directive: Annex XII – Benefit Assessment of Medicinal Products with New Active Ingredients according to Section 35a SGB V Casirivimab/ imdevimab (post-exposure prophylaxis of COVID-19 infection, ≥ 12 years; COVID-19, ≥ 12 years) (repeal of the resolutions of 6 October 2022)

From 19 March 2026

At their session on 19 March 2026, the Federal Joint Committee (G-BA) resolved to amend the Pharmaceuticals Directive (AM-RL) in the version dated 18 December 2008 / 22 January 2009 (Federal Gazette, BAnz. No. 49a of 31 March 2009), as last amended by the publication of the resolution of D Month YYYY (Federal Gazette, BAnz AT DD.MM.YYYY BX), as follows:

I. The findings on the benefit assessments of the active ingredient casirivimab/ imdevimab in Annex XII of the Pharmaceuticals Directive in the version of the resolutions of 6 October 2022 (BAnz AT 03.11.2022 B1 and BAnz AT 03.11.2022 B2) are deleted.

II. The resolution will enter into force on the day of its publication on the G-BA website on 19 March 2026.

The justification to this resolution will be published on the G-BA website at www.g-ba.de.

Berlin, 19 March 2026

Federal Joint Committee
in accordance with Section 91 SGB V
The Chair

Prof. Hecken